US Pharm. 2012;37(8):54.

Par Pharmaceutical Companies, Inc., announced that it has entered into a definitive agreement to be acquired by an affiliate of TPG in a transaction with an equity value of $1.9 billion. Par’s board of directors unanimously approved the merger agreement. The closing of the transaction is conditioned upon, among other things, the affirmative vote of the holders of a majority of Par’s outstanding shares and clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, along with other customary closing conditions. If no superior acquisition proposal is received, the transaction is expected to close in 2012, subject to the usual approvals and closing conditions.